Grace Therapeutics: A Manufacturing Setback Priced As A Death Sentence (NASDAQ:GRCE)
· seekingalpha.com
Grace Therapeutics is rated a Speculative Buy with a $4 price target, implying 57% upside after a sharp drop from a CMC-only FDA CRL. Learn more about GRCE stock here.
“Great service with in-depth research on biotech stocks. I appreciate that Dr. Sharma will take the time to review and publish reports/updates on stocks that ...